- Home
- XGN vs CMRX Comparison
XGN vs CMRX Comparison
Compare XGN & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- CMRX
- Stock Information
- Founded
- XGN 2002
- CMRX 2000
- Country
- XGN United States
- CMRX United States
- Employees
- XGN N/A
- CMRX N/A
- Industry
- XGN Medical Specialities
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- CMRX Health Care
- Exchange
- XGN Nasdaq
- CMRX Nasdaq
- Market Cap
- XGN 72.3M
- CMRX 77.1M
- IPO Year
- XGN 2019
- CMRX 2013
- Fundamental
- Price
- XGN $4.01
- CMRX $3.84
- Analyst Decision
- XGN Strong Buy
- CMRX Strong Buy
- Analyst Count
- XGN 2
- CMRX 2
- Target Price
- XGN $7.50
- CMRX $8.50
- AVG Volume (30 Days)
- XGN 197.2K
- CMRX 1.6M
- Earning Date
- XGN 11-12-2024
- CMRX 02-27-2025
- Dividend Yield
- XGN N/A
- CMRX N/A
- EPS Growth
- XGN N/A
- CMRX N/A
- EPS
- XGN N/A
- CMRX N/A
- Revenue
- XGN $55,751,000.00
- CMRX $159,000.00
- Revenue This Year
- XGN $6.81
- CMRX N/A
- Revenue Next Year
- XGN $17.72
- CMRX $1,690.28
- P/E Ratio
- XGN N/A
- CMRX N/A
- Revenue Growth
- XGN 8.00
- CMRX N/A
- 52 Week Low
- XGN $1.30
- CMRX $0.75
- 52 Week High
- XGN $6.22
- CMRX $4.07
- Technical
- Relative Strength Index (RSI)
- XGN 52.22
- CMRX 71.26
- Support Level
- XGN $2.76
- CMRX $3.25
- Resistance Level
- XGN $3.42
- CMRX $3.72
- Average True Range (ATR)
- XGN 0.53
- CMRX 0.33
- MACD
- XGN -0.01
- CMRX -0.05
- Stochastic Oscillator
- XGN 56.10
- CMRX 75.79
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.